Cardiac remodeling, characterized by excessive extracellular matrix (ECM) remodeling, predisposes the heart to failure if left unresolved. Understanding the signaling mechanisms involved in excessive extracellular matrix (ECM) remodeling is necessary to identify the means to regress the development of cardiac remodeling and heart failure. Recently, hyaluronan (HA), a ubiquitously expressed glycosaminoglycan in the ECM, was shown to participate in tissue fibrosis and myofibroblast proliferation through interacting with its ubiquitously expressed cell-surface receptor, CD44. CD44 is a multifunctional transmembrane glycoprotein that serves as a cell-surface receptor for a number of ECM proteins. The mechanism by which the interaction between CD44-HA contributes to ECM and cardiac remodeling remains unknown. A previous study performed on a non-cardiac model showed that CD44-HA enhances Na + /H + exchanger isoform-1 (NHE1) activity, causing ECM remodeling, HA metabolism and tumor invasion. Interestingly, NHE1 has been demonstrated to be involved in cardiac remodeling and myocardial fibrosis. In addition, it has previously been demonstrated that CD44 is upregulated in transgenic mouse hearts expressing active NHE-1. The role of CD44, HA and NHE1 and the cellular interplay of these factors in the ECM and cardiac remodeling is the focus of this review.
Introduction
Despite advancements in medical therapy, the global burden of heart failure remains high. Globally, heart failure affects at least 26 million people [1] . According to the American Heart Association (AHA), the annual prevalence of heart failure has increased from 5.7 million in 2012 to 6.5 million in 2014 and a 46% increase is estimated by 2030 compared to 2012 in the United States (US) alone [2] . Understanding the pathophysiological etiologies of heart failure is essential to identify novel therapeutic targets.
Cardiac remodeling, which occurs as a result of cardiac injury such as pressure overload (hypertension), volume overload (valvular regurgitation), dilated cardiomyopathy, myocardial infarction (MI) or myocarditis, contributes to adverse effects on cardiac function and predisposes the heart to failure if left unresolved. Understanding the signaling mechanisms involved in cardiac remodeling is necessary to identify the means to regress the development of heart failure. Cardiac remodeling involves cellular, molecular and interstitial changes that overt clinically as alterations in shape, size and function of the myocardium. Cardiac remodeling could be classified as physiological or pathological remodeling. Physiological remodeling is considered reversible and involves improved cardiac output with minor extracellular matrix (ECM) alterations, whereas pathological remodeling is characterized by cardiomyocyte hypertrophy, tissue fibrosis, collagen deposition, apoptosis and fibroblast proliferation, which eventually plays a role in the evolution of cardiac diseases leading to heart failure [3] [4] [5] [6] . In the myocardium, the ECM provides a structural support, coordinates electrical and chemical signals, and moderates cell proliferation, tissue repair and survival. ECM alterations and collagen deposition are distinctive features of cardiac remodeling, causing fibrosis and disrupting the architecture and plasticity of the myocardium [7, 8] . Cardiac fibroblasts, which represent about 60-70% of cells in the heart, have a critical role in maintaining ECM integrity and regulating the mechanical force distribution, chemical signals and electrical conduction between the cellular and non-cellular compartments of the heart [9] . Cardiac fibroblasts produce ECM-degrading proteins and their inhibitors, namely matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs), respectively [10] . The imbalance between ECM regulatory proteins is an underpinning reason of cardiac fibrosis and a key event of pathological cardiac remodeling [11] . Understanding the factors that contribute in maintaining ECM integrity is critical in controlling cardiac remodeling.
Various . The C-terminal cytosolic domain is also important, as it regulates the membrane domains ion exchange activity and is the site of phosphorylation, cofactor and protein interactions. Various factors including angiotensin-II (ANG-II), endothelin-1 (ET-1) and growth factors are known to trigger NHE-1, the cardiac specific NHE isoform, activity and induce an acidic extracellular environment thereby contributing to the development of cardiac remodeling [14] [15] [16] . Likewise, CD44 has been involved in cardiac remodeling and myocardial fibrosis, following MI, through interacting with its ligands, for example, hyaluronan (HA) and osteopontin (OPN) [17, 18] . Interestingly, a previous study has identified a link between CD44-HA interaction and NHE-1 activation in a cancer model, which resulted in ECM remodeling, HA degradation and tumor invasion [19] . Moreover, a very recent study has demonstrated the upregulation of CD44 in mouse hearts of transgenic mice expressing active NHE1 [20] . The role of CD44, HA and NHE1 and the cellular interplay of these factors in the ECM and cardiac remodeling is the focus of this review.
Components of the extracellular matrix: CD44 and Hyaluronan

CD44: structure
CD44, a multifunctional transmembrane glycoprotein, is widely expressed throughout the body. It is mainly found on the surface of fibroblasts, leukocytes, parenchymal cells (epithelial cells, endothelial cells and smooth muscle cells) and keratinocytes [21] . CD44 undergoes extensive alternative splicing and post translational modifications of a single encoded gene on chromosome locus 11p13 and exists in several isoforms with molecular weight of 80-250 kDa. CD44H, hematopoietic CD44, lacks the alternatively spliced exons and has a molecular weight of 80-100 kDa, while CD44s, standard CD44, has a molecular weight of 85-90 kDa and is made of exons 1-5 and 16-20. CD44v, variant CD44, on the other hand, is composed of ten variable exons 6-15 spliced at different insertion sites within the standard exons [17, 22] . CD44 has three primary domains: the extracellular domain, transmembrane domain and the cytoplasmic domain (Fig. 1) . The extracellular domain functions as a cell-surface receptor for HA, OPN, fibronectin, laminin, MMPs and collagens, as well as, cytokines and growth factors [17, 22] . The cytoplasmic domain interacts with multiple downstream signaling molecules such as RhoA-ROK, Tiam1 and Vav2, TGF-β receptors, p185
HER2 and other kinases [19] . CD44 undergoes proteolytic cleavage by membrane type-1 matrix metalloproteinase (MT1-MMP) and γ-secretase, induced by CD44 ligands, to release extracellular domain (ECD), transmembrane domain (TMD) and intracellular domain (ICD).
The ICD, has a molecular weight of 12 kDa, translocates to the nucleus to induce transcriptional genes [22] .
CD44: major ligand -hyaluronan (HA)
The interaction between CD44 and ligands result in intracellular signaling, influencing cellular responses including cell adhesion and migration of cells [23, 24] . There are a number of CD44 ligands, including, HA, MMPs, OPN and collagens, with HA being the major ligand for CD44 [22] . HA is a ubiquitous component of the mammalian ECM and a ligand of CD44 glycoprotein. It is a high molecular weight polymer of repeated disaccharides of N-acetylglucosamine and glucuronic acid units [25] . HA is primarily synthesized by mesenchymal cells including fibroblasts; its synthesis increases in settings of wound healing and tissue injury [26, 27] . Previous studies have unraveled the functional role of HA in molecular mechanisms and demonstrated the role of HA in order to develop potential therapeutic strategies against many diseases [26] . HA plays multiple roles in cardiac development, cellular proliferation, adhesion and migration, and in maintaining tissue hydration [21] . HA also functions as a co-regulatory component during wound healing, tissue repair, inflammation and tumor invasion [25] .
HA is synthesized by HA-synthase enzymes HAS-1, HAS-2, and HAS-3, and is released at the cell membrane [26] . Knockout studies of HAS-2 −/− mice embryos have shown lethal incidences due to cardiac and vascular abnormalities [28] . The catabolism of HA, which exists in a dynamic state of turnover, is regulated by hyaluronidase enzymes: HYAL-1, HYAL-2, HYAL-3, HYAL-PH20 and HYAL-SPAM1. HYAL-1 and HYAL-2 are active HA-metabolizing enzymes [29] converting high molecular weight HA (HMWHA) into low molecular weight HA (LMWHA) [26] . HYAL-2 is an acid-active enzyme and a glycosylphosphatidylinositol attached cell surface protein. CD44 plays a role in HA metabolism by facilitating HYAL enzymes. Studies have reported that HA catabolism is mediated through CD44, and HYAL-1 and HYAL-2 enzymes. LMWHA fragments at the site of inflammation mediate inflammatory effect and stimulate cardiac fibroblasts and myofibroblasts proliferation, leading to tissue fibrosis through interaction with CD44 and growth factor mediated signal transduction [29, 30] . This suggests that CD44-HA binding modulates the functioning of cardiac cells towards cardiac fibrosis and remodeling. Hence, HAS and HYAL play an important role in the metabolism of HA, which interact with CD44 to trigger intracellular signaling and cellular responses.
CD44: physiological and pathological roles during cardiac injury
CD44 is an essential protein both physiologically and pathologically: many clinical disorders occur as a result of absent or impaired CD44. CD44 has multiple physiological roles including cell interaction, cell-matrix adhesion, apoptosis, cell proliferation, differentiation, migration and permeability. Absence of CD44 results in impaired wound healing, proliferation of keratinocytes and disturbs HA metabolism [22, 31] .
During inflammation, which is commonly experienced as a result of myocardial injuries, CD44 expression on parenchymal and hematopoietic cells is upregulated [17, 32] . In asthma and atherosclerosis, CD44 was demonstrated to regulate leukocytes, including macrophages, T-cells and eosinophils, in to sites of inflammation [17] . This is mediated through the interaction of CD44 with HA, which is thought to regulate the defense mechanisms and promote phagocytosis of matrix debris and induce nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB), p38 and MAPK inflammatory pathways [18, 33] . A previous study on CD44-deficient mice subjected to myocardial infarction had shown prolonged inflammation, decreased collagen localization, reduced myofibroblasts infiltration and decreased TGF-β signaling (indicated by reduced p-smad2: total smad2 expression) [18] . Another in vivo study conducted on a mouse model following an acute MI, showed that IL-6 enhanced CD44, HAS-1 and HAS-2 expressions in cardiac fibroblasts. An increase in HAS resulted in HA rich matrix. As a result, pro-inflammatory cytokines and SM α-actin expressions were induced through CD44-HA interactions. This interaction along with circulating IL-6 has altered the nature of ECM, modulated cardiac fibroblasts differentiation and promoted immune responses [27] . This demonstrates the interrelationship between inflammatory mediators and CD44 in regulating inflammatory responses, cardiac repair processes and cardiac fibroblasts differentiation following MI.
Other proteins present in the ECM also influence inflammatory responses and cardiac function. Early MMP-12 inhibition has been demonstrated to worsen cardiac function by impairing CD44-HA interaction, increasing inflammation and reducing leukocytes elimination [34] . CD44 interacts with MMP-9, independent of HA, at sites of inflammation, leading to tissue remodeling and activation of TGF-β, which in turn downregulates inflammation and promotes tissue fibrosis [17] . Tissue fibrosis is considered a reparative mechanism to reduce the risk of tissue rupture, however over time, it predisposes the heart to failure [30] .
These findings suggest that CD44, HA and their interaction are crucial in the development of myocardial fibrosis and cardiac remodeling following myocardial infarctions and accelerates the progression to heart failure. Whether such interactions contribute to cardiac remodeling induced by volume overload, dilated cardiomyopathy or myocarditis requires further studies.
Na + /H + exchanger isoform-1
The sodium-hydrogen exchanger (NHE) is a ubiquitous transmembrane protein which consists of ten tissue specific isoforms (NHE1-10).
The main isoform present in the heart is NHE1. Each isoform has distinctive physiologic function, tissue expression and exhibits different cellular localization. NHE 1-5 are plasma membrane proteins, while NHE 6-9 are primarily expressed on intracellular organelles [35] . Under physiological conditions, NHE-1 is involved in regulating intracellular pH and cell volume. NHE-1 regulates cytosolic pH by exchanging intracellular protons for extracellular sodium. Also, it is indirectly involved in growth, cell proliferation, differentiation, migration and cytoskeleton organization [35, 36] .
The role of NHE-1 in cardiac remodeling
Increased activation and expression of NHE-1, which is triggered by inflammatory mediators, hormones, intracellular acidosis and oxidative stress, has been implicated in cardiac remodeling, hypertrophy and myocardium ischemic diseases. This resulted in increased intracellular Na + and Ca 2+ causing tissue injury [14, 15, 35, 37] . Chronic neurohormonal stimulation with ET-1, phenylephrine (PE) and ANG II promotes NHE-1 activation leading to cardiac hypertrophy [14] . NHE-1 inhibition has been demonstrated to prevent cardiac remodeling of surviving myocardium following MI [38] . Another study conducted on spontaneously hypertensive rats (SHR) demonstrated that inhibition of NHE-1 reduced cardiac hypertrophy and myocardial fibrosis [39] . It was proposed that elevated NHE1 increases OPN which in turn mediates TGF β induced myofibroblast activation and leads to fibrosis [40] . These studies suggest that NHE-1 has a role in cardiac remodeling, hypertrophy and fibrosis. Thus, targeting the NHE-1 pathway shows promising potential to suppress or reverse cardiac remodeling. Previous study has shown that inhibition of NHE activity has reduced the symptoms in isoproterenol induced cardiac hypertrophy in rats [41] . A recent study also demonstrated that specific silencing of myocardial NHE-1 with short hairpin RNA is a therapeutic strategy to reduce cardiac hypertrophy in rats [42] . The clinical development of NHE1 inhibitors quickly progressed from the bench to the bedside. The first clinical trial, GUARD During Ischemia Against Necrosis (GUARDIAN) assessed cariporide, an NHE1 inhibitor, in patients with acute coronary syndromes [43] . The benefits of cariporide were only observed in a subset of patients who underwent coronary artery bypass graft [44] . The Evaluation of the Safety and Cardioprotective effects of eniporide in the Acute Myocardial Infarction (ESCAMI) was another clinical trial using another NHE1 inhibitor, eniporide, in patients undergoing thrombolysis or angioplasty for acute myocardial infarctions [45] . In this study, the administration of eniporide did not demonstrate any significant findings [45] . The lack of beneficial effects seen in the clinical trials later were attributed to suboptimal dosing (GUARDIAN), and the timing in which the NHE1 inhibitors were administered (ES-CAMI) [46] . Another clinical trial using cariporide was conducted, the Na+/H+ Exchange inhibition to Prevent coronary Events in acute cardiac conDITIONs (EXPEDITION), which examined the effects of cariporide on mortality and the incidence of MI in high-risk patients undergoing coronary artery bypass graft surgery. In this study, cariporide reduced myocardial infarctions, however, this was paralleled by negative cerebrovascular events [43] . Hence, exploring the pathway downstream to NHE-1 that promotes cardiac remodeling is highly warranted, leading to an indirect inhibition of NHE-1, thereby evading the undesirable side effects of NHE-1 inhibitors. This review illustrated the roles of CD44, HA and NHE-1 in cardiac remodeling, myocardial fibrosis and heart failure. Previous studies have demonstrated the role of CD44-HA interaction in cardiac remodeling and myofibroblast proliferation post MI [17, 18] . Also, the role of NHE-1 in cardiac remodeling and hypertrophy has been clearly addressed by previous research studies and available literature in this area. Therefore, CD44-HA interaction and NHE-1 upregulation might coexist in the remodeled heart. A recent study has demonstrated that CD44 mRNA and protein expressions were upregulated in transgenic mice overexpressing NHE-1 [20] indicating that CD44 has a pivotal role in cardiac remodeling and hypertrophy induced by NHE-1. Bourguignon et al. conducted an in vitro study on breast cancer models, in which the interaction between CD44 and HA showed an activation of NHE-1 which further enhanced the activity of HYAL-2 enzyme and cathepsin B [19] . This resulted in increased HA metabolism, ECM deposition and tumor cell invasion [19] . It is yet unknown whether the same implication is applicable to cardiac models post cardiac injury such as MI (Fig. 2) . Hence, cardiac remodeling can be suppressed by downstream targeting of NHE1 mediated pathway, consisting of HYAL 2, HA and CD44, promoting tissue fibrosis.
Conclusion
Cardiac remodeling is a leading factor to heart failure and is characterized by increased ECM turnover. It has been shown that, CD44-HA interaction participates in ECM remodeling, tissue fibrosis and progression of heart failure. Active NHE1 has also been reported to induce cardiac remodeling leading to heart failure. CD44 has been found to be upregulated in NHE1 induced cardiac remodeling. The interplay of CD44-HA mediated by active NHE1 remains unclear in cardiac setting. Therefore, further studies on the role of CD44-HA interaction mediated by NHE-1 activation in cardiac models are required to identify novel targets that would reverse or suppress the progression of cardiac remodeling. , an acid-active enzyme, causing fragmentation of high molecular weight hyaluronan (HMWHA) into low molecular weight hyaluronan (LMWHA). The interaction between CD44, hyaluronan cell-surface receptor, and LMWHA activates TGF-β receptor and induces Smad signaling pathway (Smad 2,3 and Smad 4) required for collagen deposition, cardiac remodeling and heart failure.
